BridgeBio announces voluntary U.S. government agreement to expand Medicaid access, avoid pricing mandates

BridgeBio Pharma, Inc.

Voluntary agreement with U.S. government expands Medicaid access to Attruby via GENEROUS Model; specific terms confidential.
BridgeBio expects no future pricing mandates; pricing commitments exclude medicines approved exclusively for orphan indications.
CEO Neil Kumar joined President Trump at White House to announce deal; no impact on ForgingBridges copay program ($0/mo for qualifying patients).
Three drugs under FDA review: BBP-418 (PDUFA Nov 27, 2026), encaleret (PDUFA May 7, 2027), infigratinib for achondroplasia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.